About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Letters to the Editor
Health Care & Law
Part 1: Deconstructing Dispensing Errors
A comprehensive analysis of malpractice claims experience from a professional liability insurer, Healthcare Providers Service Organization, can help P&T committees better understand the risks and challenges they encounter each day.
James O’Donnell, PharmD; and F. Randy Vogenberg, RPh, PhD
A Number of Efforts Are Under Way to Reduce Price Pressure
Organizations are trying to address the high cost of “specialty” medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.
Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.
Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD
Attendees at the 19th Congress of the European Hematology Association in Milan, Italy, heard reports on new therapies for acute myeloid leukemia, chronic lymphocytic leukemia, β-thalassemia, multiple myeloma, and polycythemia vera.
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
Kunj Gohil, PharmD, RPh; and Brielle Carramusa
A Patient Verification Process Is Needed Everywhere, Not Just at the Bedside
Matthew Grissinger, RPh, FASCP
QHPs Must Respond Within 24 Hours to “Expedited” Requests
FDA approvals, drug indications, and updates
Vedolizumab (Entyvio) for ulcerative colitis and Crohn’s disease; dalbavancin (Dalvance) for acute bacterial skin and skin structure infections; and antihemophilic factor, recombinant (Eloctate) for hemophilia A
Marvin M. Goldenberg, PhD, RPh, MS
A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections
Elaine Wong, PharmD, BCPS; and Saba Rab, PharmD, BCPS